Lumos Secures 100% US Medicare Reimbursement for FebriDx
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. has announced that it has secured full Medicare reimbursement recognition for its product FebriDx from all Medicare Administration Contractors in the U.S. This achievement allows for reimbursement at a specified rate per test and is expected to facilitate broader adoption of FebriDx across the U.S. healthcare system. The company will now focus on assisting the contractors in developing written policies to streamline reimbursement claims management. This recognition is significant as it also benefits Medicare Advantage and Medicaid plans, which often reference Medicare fee schedules for their own reimbursement frameworks.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- Lumos secures follow-on PKU contract with Aptatek
- LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
- FY25 Appendix 4E
- Lumos Announces FebriDx CLIA Waiver Application Submission
- Lumos Signs Binding Term Sheet for A$5M Loan Facility
Later from Lumos Diagnostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Lumos Completes Enrolment Milestone for Paediatric Study
- Appendix 4D and Half Year Report
- Lumos Delivers Several Pivotal Milestones in 1H FY26
- Trading Halt
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics